• Nuubo

  Participated · Equity · Oct 2022

  NUUBO develops textile medical electronics and wireless sensors for cardiac monitoring, including a system that records ECG to detect and diagnose irregular heart rhythms and help prevent cardiovascular events. The company was founded in 2005 and has offices in Paterna and Madrid. NUUBO’s monitoring system is positioned toward clinical detection of arrhythmias and cardiovascular risk prevention. The company closed a €270,000 financing intended to support its expansion into the United States. The financing was led by a health-focused coinvestment vehicle, reflecting investor interest from public and private backers. No operating metrics were disclosed in the article. Nuubo designs, manufactures and sells a proprietary wearable wireless ECG system comprised of a comfortable textile Holter (no adhesives, no wires) and arrhythmia analysis software. The CE-marked system offers up to 60 days of cardiac monitoring and has demonstrated over 20% diagnostic yield for atrial fibrillation in cryptogenic stroke during a 30-day monitoring period. The product fills a gap between short-term non-invasive monitors (7–14 days) and long-term invasive implants, targeting improved detection of arrhythmias such as atrial fibrillation. Nuubo holds several patents in the EU and USA and is certified to ISO 27001, ISO 13485 and ISO 9001. The company is headquartered in Madrid with R&D and manufacturing facilities in Valencia, Spain, and is supported by Spanish VCs including Cross Roads Biotech Inverbio, Caixa and Fides Capital. The announced financing is intended to accelerate growth, expand commercial presence in Europe and the US, and fund clinical trials and new product development. Nuubo develops biomedical garments and a platform that simplify heart monitoring by enabling continuous, cable-free electrocardiogram (ECG) readings in dynamic environments. Its platform, the nECG DYNAMIC PLATFORM, allows users to perform and read ECGs remotely. The company says its solution removes the need for cables, requiring only a piece of clothing to monitor cardiac activity. Nuubo started commercial activities in 2012 and has a production centre in Paterna (Valencia) and 22 employees in Madrid. It intends to use the new funds to position itself in the main European markets. The company expects to exceed €1m in sales in 2014.

• Amadix

  Led · Equity · Oct 2020

  Amadix develops tests for early cancer diagnosis that combine molecular analysis with big data and artificial intelligence. The company received a €2.5M grant from the European Innovation Council (EIC) Accelerator. It has begun procedures to obtain a second, €6M equity tranche under the same program. Sodical is a shareholder in Amadix. The EIC selection was highly competitive — more than 4,000 SMEs applied and only 99 were chosen (2.4% success rate). Amadix was among the selected projects led by women (part of the 19% statistic). The funding is intended to accelerate continued development of its diagnostic tests. Amadix, founded in 2010 and based in Valladolid, develops non-invasive blood tests for early cancer screening and molecular diagnosis. Its lead product, ColoFast, is designed to detect colorectal cancer even before symptoms appear. The company also has two tests in development targeting lung and pancreatic cancer. With the new investment, Amadix will complete the clinical validation of ColoFast in Europe. The company estimates it will bring ColoFast to market during 2021. Amadix positions its technology as a simple, high-compliance screening method able to detect precancerous lesions in asymptomatic individuals. Amadix is a biotech firm focused on diagnostic tools in oncology, with its Colofast test designed to detect colon cancer up to fifteen years before symptoms. The company is also developing Diagnolung (early lung‑cancer detection) and Pancreadix (early pancreatic‑cancer detection), both currently in clinical validation. Amadix plans to commercialize its technology from 2020 and is targeting the US and European markets, with interest in exploring China. The company has received prior funding including €2.8M in 2017 following a Horizon 2020 aid and more than €0.5M later from Alentia, and was named best startup at South Summit 2018. Amadix is based in Valladolid. Amadix merged with Transbiomed and focuses on developing diagnostics for lung, colon and prostate cancers. The company is led by Rocío Arroyo and intends to use new funds to continue developing its pipeline and to acquire new biomarkers. Following the transaction, Amadix’s shareholder base includes CRB Bio II FCR, Inveready Seed Capital SCR, Fondo Tecnológico Seguranza FCR, ADE Capital Sodical SCR and the founders of Transbiomed. The deal comprised a €2m financing package, with €1.5m committed by CRB Bio II and €0.5m by Inveready, alongside various public credit financings. The merger with Transbiomed and the fresh capital are positioned to support continued R&D and biomarker acquisition efforts.

No current team members are available.